QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO): Changing The Field Of Regenerative Medicine With Unique, Self-Sustaining Business Model 1 comment
    Jan 28, 2014 5:40 PM | about stocks: ISCO

    International Stem Cell is focused on exploring and advancing the therapeutic applications of human stem cells as well as the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells, parthenogenetic stem cells, created from unfertilized human eggs, and has established a strong patent portfolio offering clean intellectual property and freedom to operate.

    Utilizing a strategy much different than the majority of other players in the biotech space, International Stem Cell generates revenues from its individual subsidiary business units that sell products developed from scientific discoveries made by International Stem Cell. Not only is this model self-sustaining with revenues used to support scientific research and development, it also provides practical, short-term applications of the core technologies.

    The Lifeline Cell Technology (LCT) and Lifeline Skin Care (NYSEARCA:LSC) commercial businesses provide the foundation for International Stem Cell's short-term application. For the six-months ended June 30, 2013, International Stem Cell reported revenues of $2.74 million, compared to revenues of $2.13 million for the prior year period. LCT contributed $1.38 million, up 30 percent year-over-year, while LSC contributed $1.36 million, an increase of 27 percent from the same period in 2012.

    Therapeutic programs, including those addressing Parkinson's disease, metabolic liver disease and corneal blindness, make up International Stem Cell's medium-term applications. In regards to its Parkinson's disease program, International Stem Cell has carried out several stem cell-based experiments and recently concluded its first pilot primate study with favorable results. In mid-2104, the company plans to submit to the U.S. FDA an investigational new drug (NYSE:IND) application, and recently engaged Duke University as a partner to carry out the phase I clinical study of Parkinson's disease in human subjects.

    International Stem Cell's long-term strategy is focused on therapeutic products, licensing revenue and the company's stem cell bank, UniStemCell, the life science industry's first collection of non-embryonic histocompatible human stem cells available for research and commercial use.

    Each aspect of International Stem Cell's business model is centered on the company's proprietary stem cell technology. The company's stem cells present superior immune matching capabilities and can be used in millions of people, regardless of their sex or racial background, with minimized expectation of immune rejection following transplantation.

    For more information visit internationalstemcellcorp.com

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • Splenosis
    , contributor
    Comments (22) | Send Message
    Love this company. Hope 2014 is a great year for them!
    29 Jan 2014, 04:40 PM Reply Like
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.